Improving Visibility of the Pharma Supply Chain: Best Practices and Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Visibility of the Pharma Supply Chain: Best Practices and Technologies
The authors review current industry challenges and trends in managing global supply chains and propose best practices for improving visibility into those networks.


Pharmaceutical Technology
Volume 35, pp. s26-s33

Conclusion

To realize the benefits of globalization, companies must implement new strategies that capitalize on the benefits of globalization and outsourcing while reducing and controlling risks. This article has outlined key challenges to managing global life-sciences product supply chain and proposed approaches for maintaining better visibility and control over those product life cycles. Simply put, it requires the use of information that is readily available, managed correctly, and shared to help to ensure the safety, efficacy, and quality of products for all parties involved.

David J. Lennard is vice-president, and Daniel R. Matlis is founder and president, both of Axendia,
.

To read Matlis' report on outsourcing's effect on process analytical technology and quality by design, see "Has Outsourcing Derailed PAT and QbD?"

References

1. Axendia, "Achieving Global Supply Chain Visibility, Control & Collaboration in Life Sciences: Business Imperative, Regulatory Necessity" (2010), http://www.axendia.com/2010_LS_GSC.html.

2. US IPEC, "Joint Strategic Plan on Intellectual Property Enforcement" (Washington, DC, June 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here